Abstract: An infusion system is provided and includes: a three-way valve, provided with a first liquid inlet for an intravenous infusion liquid, a second liquid inlet configured for a syringe liquid and a liquid outlet communicating with a venipuncture needle; an information matching structure, including a first identification code configured for identifying identity information of the three-way valve and an identifier configured for identifying the first identification code; a detection structure, including a first flow sensor configured for detecting a liquid flow rate at the first liquid inlet, a second flow sensor configured for detecting a liquid flow rate at the liquid outlet and a pressure sensor configured for detecting a pressure at the liquid outlet; and a controller, is capable of acquiring identity information, flow and pressure information, recording the information to corresponding identity information items and giving an alarm when the information is abnormal.

Abstract: The present invention discloses a bladder cancer detection kit and detection method. The kit includes a DHFR PCR reaction solution, a Twist1 and TSC21 PCR reaction solution, a point mutation positive control, a methylation positive control and a negative control. According to the present invention, by detecting the point mutation of a DHFR gene and the methylation level of a promoter region of TSC21 and Twist1 genes in a sample, the joint detection of gene point mutation and methylation is achieved for determining whether the sample is cancerous. The kit is convenient and simple to operate, high in detection sensitivity and high in specificity, and has a very positive significance in the detection of bladder cancer.

Abstract: Provided is a bispecific antibody targeting CD3 and a tumor target and a use of the bispecific antibody. The bispecific antibody comprises a first antigen binding region, a second antigen binding region, and an Fc portion; the Fc portion comprises a first Fc peptide fragment and a second Fc peptide fragment; the first antigen binding region comprises an scFv fragment and a binding protein or fragment thereof of a first molecule, the binding protein or fragment thereof of the first molecule is linked to the N-terminal of the scFv fragment, and the C-terminal of the scFv fragment is linked to the N-terminal of the first Fc peptide fragment; the second antigen binding region comprises a binding protein or fragment thereof of a second molecule; and the first molecule and the second molecule are the identical, and the scFv fragment has CD3 binding activity.

Abstract: Provided are an anti-CD3 antibody or an antigen binding fragment thereof and a use thereof. The anti-CD3 antibody includes heavy chain variable region CDRs and light chain variable region CDRs, the heavy chain variable region CDRs having amino acid sequences as set forth in any one of SEQ ID NOs: 1 to 3, 7 to 8, and 74 to 86, or a conservative modification form thereof, and/or the light chain variable region CDRs having amino acid sequences as set forth in any one of SEQ ID NOs: 4 to 6, 9, and 87 to 92, or a conservative modification form thereof.

Abstract: The application provides an anti-TIGIT antibody or an antigen-binding fragment thereof, and a use thereof. The anti-TIGIT antibody or the antigen-binding fragment thereof comprises heavy chain variable regions CDR1, CDR2 and CDR3 with sequences as set forth in SEQ ID NOs: 1, 2 and 3; and light chain variable regions CDR1, CDR2 and CDR3 with sequences as set forth in SEQ ID NOs: 4, 5 and 6.

Abstract: The present disclosure relates to the field of biomedicine, and more particularly, to an anti-PD-L1 antibody or antigen binding fragment and use thereof. The anti-PD-L1 antibody or antigen binding fragment according to the present disclosure includes a CDR selected from at least one of the following sequences or amino acid sequences having at least 80% identity thereto: heavy chain variable region CDR sequences: SEQ ID NO: 1, SEQ ID NO: 2, or SEQ ID NO: 3; or light chain variable region CDR sequences: SEQ ID NO: 4, WAS, or SEQ ID NO: 5. The antibody has a high binding affinity to PD-L1, and the present disclosure also provides a CD3 and PD-L1 bispecific antibody that has a stronger binding to tumor cells and promotes T cells to exert anti-cancer function.

Abstract: An anti-CD94 antibody and a use thereof. The antibody comprises heavy chain CDR1, CDR2, and CDR3, and light chain CDR1, CDR2, and CDR3, wherein: the amino acid sequences of the heavy chain CDR1, CDR2, and CDR3 respectively have at least 80% homology with the sequences represented by SEQ ID NOs 1, 2, and 3, and the amino acid sequences of the light chain CDR1, CDR2, and CDR3 respectively have at least 80% homology with the sequences represented by SEQ ID NOs 4, 5, and 6.

Abstract: Disclosed is a preparation method for a low-color number, low-odor polyisocyanate curing agent. The preparation method comprises a step of carrying out a polymerization reaction on a diisocyanate monomer under the action of a trimerization catalyst in a polymerization reaction kettle with continuously flowing inert gas, an upper head of the polymerization reaction kettle being provided with an inert gas inlet pipe, the inert gas inlet pipe being an insertion pipe, and the upper head of the polymerization reaction kettle also being provided with an inert gas outlet and a central stirring shaft; the insertion opening position (A) of the inert gas inlet pipe and the inert gas outlet position (B) on the surface of the upper head form an angle ? (?ACB) with the fixed position (C) of the central stirring shaft projected onto the plane on the upper head surface, where 30°???180°.

Abstract: Provided is an antibody or antigen-binding fragment. The antibody or antigen-binding fragment includes a CDR selected from at least one of: heavy chain variable region CDRs with amino acid sequences as set forth in SEQ ID NO: 1 to SEQ ID NO: 3, SEQ ID NO: 7 to SEQ ID NO: 9, or SEQ ID NO: 13 to SEQ ID NO: 15, or conservative modification forms thereof; or light chain variable region CDRs with amino acid sequences as set forth in SEQ ID NO: 4 to SEQ ID NO: 6, SEQ ID NO: 10 to SEQ ID NO: 12, or SEQ ID NO: 16 to SEQ ID NO: 18, or conservative modification forms thereof.

Abstract: Provided in the present invention are an anti-CD155 antibody and the use thereof. Moreover, an obtained anti-CD155 chimeric antibody, a humanized anti-CD155 antibody, and a humanized affinity-matured anti-CD155 antibody can only specifically target and bind to a CD155 receptor and block the binding of CD155 to receptors TIGIT, CD96, and CD226 thereof, but also have the characteristic of not inducing the apoptosis of CD155 cells.

Abstract: Provided are an anti-CD16A antibody and an application thereof. The antibody comprises heavy chain variable regions CDR1, CDR2, CDR3 sequences as shown in SEQ ID NOs: 1, 2, and 3, or amino acid sequences at least 95% identity to SEQ ID NOS: 1, 2, and 3; and/or light chain variable regions CDR1, CDR2, CDR3 sequences as shown in SEQ ID NOS: 4, 5, and 6, respectively, or amino acid sequences at least 95% identity to SEQ ID NOs: 4, 5, and 6.

Abstract: An atomizer includes: a liquid cup provided with a cup mouth and a mist outlet, a liquid storage tank being provided in the liquid cup; an atomization assembly including an atomization tube, a liquid guide part, and a heating part disposed inside the liquid guide part, the atomization tube being sleeved on an outer peripheral side of the liquid guide part and connected with the mist outlet and being provided with a liquid inlet so that the liquid guide part is connected with the liquid storage tank; and a base assembly including a base and a sealing member, the sealing member including a protrusion extending toward the mist outlet to be inserted into an end of the liquid guide part, the sealing member fitting with at least part of an inner wall of the liquid guide part to seal an inner side of the liquid guide part.

Abstract: An atomizer includes: a liquid cup provided with a mist outlet; an atomization assembly including an atomization tube, a liquid guide part, and a heating part disposed inside the liquid guide part, the atomization tube being sleeved on an outer peripheral side of the liquid guide part and having a first end connected with the mist outlet and a second end provided with a liquid inlet; and a sealing member including a support part and a protrusion. The support part abuts against an inner wall of the liquid cup. The support, the liquid cup and the atomization tube forms a liquid storage tank. The protrusion extends into the liquid guide part from an end of the liquid guide part away from the mist outlet. The support part is provided with at least one ventilation passage for connecting the liquid storage tank with atmosphere.

Abstract: A portable multifunctional soccer goal includes a fabric portion and a supporting structure. The fabric portion includes a left fabric portion, a right fabric portion and a back fabric portion. The back fabric portion includes a mesh, a left long strip fabric portion and a right long strip fabric portion. The supporting structure includes an upper crossbar, a lower crossbar, a middle crossbar, a left triangular frame and a right triangular frame. The left and right triangular frames are respectively positioned at two ends of the crossbars and covered by the left and right fabric portions. The lengths of the crossbars are identical and greater than the sum of lateral widths of the left long strip fabric portion and the right long strip fabric portion. The left and right long strip fabric portions can be joined by a connector when the soccer goal is being transformed into a bag.

Abstract: Disclosed are an atomizing device, an assembling method, and an aerosol generating device. The atomizing device includes a liquid storage container, an atomizing assembly, and a base assembly. The liquid storage container includes an outer shell and an atomized liquid guide tube connected to the outer shell, and an atomized liquid outlet is disposed at the connection between the atomized liquid guide tube and the outer shell. The atomizing assembly includes a first end and a second end opposite to each other, the first end is engaged with the atomized liquid guide tube. The base assembly includes a convex structure and a support portion connected to the convex structure. The convex structure is engaged with the second end. The support portion is engaged with an end of the outer shell away from the atomized liquid outlet.

Abstract: Disclosed is an atomizing device, including: a housing, in which a first installation space and a host compartment are formed, the first installation space being spaced apart from the host compartment; an oil storage structure disposed in the first installation space and containing an oil storage chamber for storing oil; an atomizing tube disposed in the oil storage structure, in which an oil inlet is disposed at an air inlet end of the atomizing tube; an atomizing core disposed in the atomizing tube and spaced from the air inlet end of the atomizing tube in a longitudinal direction of the oil storage structure; and an oil guide member disposed between the atomizing tube and the atomizing core, in which the oil guide member is connected with the atomizing core, and is in communication with the oil storage chamber through the oil inlet.

Abstract: An electronic atomization device includes: an outer shell; and an inner shell provided in the outer shell. The inner shell includes a liquid storage cup and a battery compartment arranged side by side and independent of each other. A battery and a light strip are provided in the battery compartment. The battery is configured to supply power to the light strip. At least part of the outer shell and at least part of the battery compartment are made of a light-transmitting material.

Abstract: Disclosed are an atomizer and an aerosol generating device. The atomizer includes: an atomizer tube, one or more liquid inlet holes being disposed on a side wall of the atomizer tube; a liquid reservoir disposed on an outer side of the atomizer tube and fluidly interconnected with the atomizer tube through the liquid inlet holes; a liquid-conducting member fitted to an inner side wall of the atomizer tube and connected to the liquid inlet holes; an atomizing assembly disposed in the atomizer tube and in contact with the liquid-conducting member, wherein the atomizing assembly is positioned higher than the liquid inlet holes in an axial direction of the atomizer tube.

Abstract: Provided are an antibody or an antigen-binding fragment thereof and use thereof. The antibody or antigen-binding fragment thereof includes light chain variable region CDRs and heavy chain variable region CDRs. A heavy chain variable region CDR1 sequence is as set forth in GFTFSSYX1, where X1 is Y or M. A heavy chain variable region CDR2 sequence is as set forth in INSQGGST. A heavy chain variable region CDR3 sequence is as set forth in ARSDYDWAWX2AY, where X2 is For Y. A light chain variable region CDR1 sequence is as set forth in QSLLYSSNQKNY. A light chain variable region CDR2 sequence is as set forth in WAX3, where X3 is S or N. A light chain variable region CDR3 sequence is as set forth in QQYYRYPPT.

Abstract: Provided are an antibody or antigen-binding fragment thereof, and application thereof. The antibody or the antigen-binding fragment thereof includes: heavy chain variable region CDR1, CDR2 and CDR3 sequences as set forth in SEQ ID NO: 1, SEQ ID NO: 2, and SEQ ID NO: 3 or as set forth in amino acid sequences having at least 80% identity to SEQ ID NO: 1, SEQ ID NO: 2, and SEQ ID NO: 3; and light chain variable region CDR1, CDR2 and CDR3 sequences as set forth in SEQ ID NO: 4, SEQ ID NO: 5, and SEQ ID NO: 6 or as set forth in amino acid sequences having at least 80% identity to SEQ ID NO: 4, SEQ ID NO: 5, and SEQ ID NO: 6.